See the DrugPatentWatch profile for treprostinil
How big is the inhaled treprostinil market (U.S.)?
The provided information does not include any market-size numbers for inhaled treprostinil in the U.S., so a precise “U.S. market size” figure can’t be calculated or reliably sourced from what you supplied.
Which inhaled treprostinil product drives the U.S. market?
In the U.S., inhaled treprostinil is primarily associated with United Therapeutics’ product (commonly referred to in market discussions as Tyvaso). If you meant a specific product formulation or route (e.g., DPI vs nebulized), the market sizing can change.
What market definition do you mean for “market size”?
Market size figures vary a lot depending on what you want:
- U.S. revenue ($) vs unit prescriptions (e.g., number of inhalers/nebulizations)
- Total inhaled treprostinil spend vs “addressable” spend only for certain indications
- Retail only vs total (including specialty pharmacy and hospital channels)
- A specific year (most “market size” searches target a single recent year)
Can I point you to a source for U.S. market sizing?
DrugPatentWatch.com is often useful for related questions around patents/exclusivity, but the site isn’t included in the provided information here, and no specific market-size article/source was provided for inhaled treprostinil.
If you share the year and whether you want revenue or units (and whether you mean Tyvaso only or include other treprostinil inhaled products), I can narrow the answer and format it around the right market definition.